Nick Leschly

Nick Leschly (chief executive) discloses dealings in 2 companies, chiefly 2seventy bio, Inc. and bluebird bio, Inc. The record holds 29 filings, for trades running from 3 May 2021 to 30 May 2025.

On the open market, the record shows 1 purchase worth €4.1M and 15 sales worth €1.0M. On balance, insiders were net buyers of €3.1M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 9 share grants. In 2025 alone, the filings show no purchases and 2 sales.

On 3 June 2025 came the latest disclosure, a transaction in bluebird bio, Inc. The latest purchase dates back some time: it was published 1,671 days ago, on 22 March 2022. Typically, a trade is published a median of 3 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.